Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) (NCT05546580)
An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+): The FRIDA Study
🩺 Plain-English Summary (8th-Grade Level)
Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat will be given in combination with gilteritinib, a drug that is already approved to treat patients with FLT3-mutated R/R AML.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- The University of Arizona Cancer Center - North Campus — Tucson, Arizona
- Sylvester Comprehensive Cancer Center — Miami, Florida
- Miami Cancer Institute — Miami, Florida
- The John Hopkins University School of Medicine — Baltimore, Maryland
- Massachusetts General Hospital (MGH) — Boston, Massachusetts
- Rutgers, The State University — Piscataway, New Jersey
- Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital — New York, New York
- Duke University Medical Center — Durham, North Carolina
- Oregon Health & Science University — Portland, Oregon
- Sarah Cannon Research Institute, LLC — Nashville, Tennessee
- West Virginia University — Morgantown, West Virginia
- Froedtert Hospital & The Medical College of Wisconsin — Milwaukee, Wisconsin
📞 Contact the Study Coordinator
Phone: (877) 632-6789
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Myeloid Leukemia, in Relapse
- A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies — Charlotte, North Carolina
- Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS — Charlotte, North Carolina
- Venetoclax to Augment Epigenetic Modification and Chemotherapy — Milwaukee, Wisconsin
- A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) — La Jolla, California
- Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia — Charlottesville, Virginia
Explore by condition: All Acute Myeloid Leukemia, in Relapse clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.